A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pneumonia Community-Acquired Infections Community-Acquired Pneumonia Infections Inflammation Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Respiratory Tract Infections Sepsis Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

ICOS Corporation

Bothell, Washington, 98021, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Current diagnosis of community-acquired pneumonia.
Evidence of systemic inflammatory response to infection.

Exclusion criteria

Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the investigator.
Presence of organ failure.

Treatment and study plan

Recombinant Chimeric Monoclonal Antibody

Drug

Sponsors and collaborators

Lead sponsor

ICOS Corporation

Industry

Registry information

Official study title

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

Important dates

Study start: 2002
First posted: Aug 5, 2002
Registry last updated: Jun 24, 2005

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed